Anzeige
Mehr »
Login
Montag, 17.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Kennen wir bei East Africa bislang nur die Spitze des Goldberges?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
289 Leser
Artikel bewerten:
(1)

Ananda Developments Plc - Update on Medical Cannabis Growing Licence

Ananda Developments Plc - Update on Medical Cannabis Growing Licence

PR Newswire

7 April 2020

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

UPDATE ON MEDICAL CANNABIS GROWING LICENCE

The Directors of Ananda Developments Plc provide the following update to shareholders.

The Home Office application

A second round of questions relating to the application to grow >0.2% THC cannabis has been received from The Home Office. Responses are being formulated and it is expected that a physical visit to the growing location will be undertaken by Home Office representatives in the next couple of months, subject to the lock down requirements of the COVID-19 emergency.

MHRA

In addition, the MHRA (Medicines and Healthcare Regulatory Agency) has requested a meeting to discuss the application, its research aims and objectives, and how the objectives will assist in progressing the medical cannabis sector in the UK.

Ananda's Medical Cannabis Growing Plans

Ananda has a see through 50% interest in DJT Plants Limited ("DJT") which has made an application to grow >0.2% THC cannabis in Lincolnshire. Its partner is the JEPCO Group, comprised of JEPCO Limited and Anglia Salads Limited ("JEPCO"). DJT's proposal is to commence growing up to 1,105 cannabis plants in Lincolnshire, and to ultimately increase to growing on an area up to 30 hectares (accommodating approximately 300,000 cannabis plants). The practical growing will be undertaken by JEPCO, which has previously grown medical cannabis in the UK for a large pharmaceutical company.

The initial objective is to stabilise 13 strains of cannabis to have low variability and high predictability, in collaboration with Dr Dedi Meiri's laboratory in Israel, which it is hoped may be useful to treat a range of conditions such as Parkinson's Disease, epilepsy and neuropathic pain. The Directors believe that Dr Meiri is one of the world's foremost researchers in medical cannabis, with one of the most sophisticated cannabis analytical laboratories in the world. Ananda's ultimate objective is to convert the genetic stabilisation growing to commercial growing, when demand builds in the UK medical cannabis industry and when the regulatory and legal framework allows.

JEPCO has successfully grown medical cannabis in the UK to very high standards, (for the pharmaceutical industry) and at low cost. The Directors believe a UK source of medical cannabis will be well received, especially given the possibility of global supply chains continuing to break down.

DJT Plants Limited is a wholly owned subsidiary of DJT Group Limited which is 50% owned by Tiamat Agriculture Limited, which is a 100% subsidiary of Ananda Developments Plc.

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

ANANDA DEVELOPMENTS PLC
Chief Executive Officer
Melissa Sturgess

Investor Relations
Jeremy Sturgess-Smith
+44 (0)7717 573 235
ir@anandadevelopments.com
PETERHOUSE CAPITAL LIMITED
Corporate Finance
Mark Anwyl
Allie Feuerlein

Corporate Broking
Lucy Williams
Duncan Vasey
+44 (0)20 7469 0930
STANFORD CAPITAL PARTNERS LIMITED
Joint Corporate Broker
John Howes
Patrick Claridge
+44 (0)20 3815 8880
CELICOURT COMMUNICATIONS
Mark Antelme
Ollie Mills
+44 (0)20 8434 2643

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.